1887

Abstract

Human metapneumovirus (hMPV), a newly discovered paramyxovirus, is associated with acute respiratory-tract illness, primarily in young children, individuals with underlying disease and the elderly. Two genetic lineages of hMPV circulate around the world, and viruses from these two lineages demonstrate antigenic differences. The clinical impact of hMPV warrants the development of vaccines. Recombinant soluble fusion (F) proteins of prototype viruses of the two main lineages of hMPV that can be produced in high yields have been constructed. In this study, the antigenicity, immunogenicity and protective efficacy of these soluble F subunit vaccines were evaluated in Syrian golden hamsters (). Immunization of hamsters with the soluble F proteins, adjuvanted with Specol or iscom matrix, induced high virus-neutralization titres, with higher titres against the homologous than the heterologous virus. The neutralizing antibodies protected from subsequent infection of the lungs with both homologous and heterologous virus. Upon challenge, viral titres in the nasal turbinates of immunized animals were reduced significantly compared with those of PBS-immunized animals. In conclusion, a soluble F subunit vaccine for hMPV that induces cross-protective immunity for infection of the lower respiratory tract in Syrian golden hamsters has been generated.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.83084-0
2007-10-01
2019-11-20
Loading full text...

Full text loading...

/deliver/fulltext/jgv/88/10/2702.html?itemId=/content/journal/jgv/10.1099/vir.0.83084-0&mimeType=html&fmt=ahah

References

  1. al-Shakhshir, R., Regnier, F., White, J. L. & Hem, S. L. ( 1994; ). Effect of protein adsorption on the surface charge characteristics of aluminium-containing adjuvants. Vaccine 12, 472–474.[CrossRef]
    [Google Scholar]
  2. Bebbington, C. R., Renner, G., Thomson, S., King, D., Abrams, D. & Yarranton, G. T. ( 1992; ). High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology (N Y) 10, 169–175.[CrossRef]
    [Google Scholar]
  3. Beck, I., Gerlach, H., Burkhardt, E. & Kaleta, E. F. ( 2003; ). Investigation of several selected adjuvants regarding their efficacy and side effects for the production of a vaccine for parakeets to prevent a disease caused by a paramyxovirus type 3. Vaccine 21, 1006–1022.[CrossRef]
    [Google Scholar]
  4. Cseke, G., Wright, D. W., Tollefson, S. J., Johnson, J. E., Crowe, J. E., Jr & Williams, J. V. ( 2007; ). Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats. J Virol 81, 698–707.[CrossRef]
    [Google Scholar]
  5. Davis, I. D., Chen, W., Jackson, H., Parente, P., Shackleton, M., Hopkins, W., Chen, Q., Dimopoulos, N., Luke, T. & other authors ( 2004; ). Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans. Proc Natl Acad Sci U S A 101, 10697–10702.[CrossRef]
    [Google Scholar]
  6. Deng, X., Meyers, S. A., Tollner, T. L., Yudin, A. I., Primakoff, P. D., He, D. N. & Overstreet, J. W. ( 2002; ). Immunological response of female macaques to the PH-20 sperm protein following injection of recombinant proteins or synthesized peptides. J Reprod Immunol 54, 93–115.[CrossRef]
    [Google Scholar]
  7. Falsey, A. R. & Walsh, E. E. ( 1996; ). Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine 14, 1214–1218.[CrossRef]
    [Google Scholar]
  8. Frazer, I. H., Quinn, M., Nicklin, J. L., Tan, J., Perrin, L. C., Ng, P., O'Connor, V. M., White, O., Wendt, N. & other authors ( 2004; ). Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 23, 172–181.[CrossRef]
    [Google Scholar]
  9. Gupta, R. K. ( 1998; ). Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 32, 155–172.[CrossRef]
    [Google Scholar]
  10. Hancock, G. E., Smith, J. D. & Heers, K. M. ( 2000; ). Serum neutralizing antibody titers of seropositive chimpanzees immunized with vaccines coformulated with natural fusion and attachment proteins of respiratory syncytial virus. J Infect Dis 181, 1768–1771.[CrossRef]
    [Google Scholar]
  11. Herfst, S., de Graaf, M., Schickli, J. H., Tang, R. S., Kaur, J., Yang, C. F., Spaete, R. R., Haller, A. A., van den Hoogen, B. G. & other authors ( 2004; ). Recovery of human metapneumovirus genetic lineages a and B from cloned cDNA. J Virol 78, 8264–8270.[CrossRef]
    [Google Scholar]
  12. Kim, H. W., Canchola, J. G., Brandt, C. D., Pyles, G., Chanock, R. M., Jensen, K. & Parrott, R. H. ( 1969; ). Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89, 422–434.
    [Google Scholar]
  13. Kuiken, T., Van Den Hoogen, B. G., Van Riel, D. A., Laman, J. D., Van Amerongen, G., Sprong, L., Fouchier, R. A. & Osterhaus, A. D. ( 2004; ). Experimental human metapneumovirus infection of cynomolgus macaques (Macaca fascicularis) results in virus replication in ciliated epithelial cells and pneumocytes with associated lesions throughout the respiratory tract. Am J Pathol 164, 1893–1900.[CrossRef]
    [Google Scholar]
  14. Lamb, R. A., Paterson, R. G. & Jardetzky, T. S. ( 2006; ). Paramyxovirus membrane fusion: lessons from the F and HN atomic structures. Virology 344, 30–37.[CrossRef]
    [Google Scholar]
  15. Leenaars, P. P., Hendriksen, C. F., Angulo, A. F., Koedam, M. A. & Claassen, E. ( 1994; ). Evaluation of several adjuvants as alternatives to the use of Freund's adjuvant in rabbits. Vet Immunol Immunopathol 40, 225–241.[CrossRef]
    [Google Scholar]
  16. Lindblad, E. B. ( 2004; ). Aluminium compounds for use in vaccines. Immunol Cell Biol 82, 497–505.[CrossRef]
    [Google Scholar]
  17. Munoz, F. M., Piedra, P. A. & Glezen, W. P. ( 2003; ). Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 21, 3465–3467.[CrossRef]
    [Google Scholar]
  18. Murphy, B. R., Sotnikov, A., Paradiso, P. R., Hildreth, S. W., Jenson, A. B., Baggs, R. B., Lawrence, L., Zubak, J. J., Chanock, R. M. & other authors ( 1989; ). Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine 7, 533–540.[CrossRef]
    [Google Scholar]
  19. Piedra, P. A., Cron, S. G., Jewell, A., Hamblett, N., McBride, R., Palacio, M. A., Ginsberg, R., Oermann, C. M. & Hiatt, P. W. ( 2003; ). Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine 21, 2448–2460.[CrossRef]
    [Google Scholar]
  20. Reed, L. J. & Muench, H. ( 1938; ). A simple method of estimating fifty percent end points. J Hyg (Lond) 27, 493–497.
    [Google Scholar]
  21. Russell, C. J., Jardetzky, T. S. & Lamb, R. A. ( 2001; ). Membrane fusion machines of paramyxoviruses: capture of intermediates of fusion. EMBO J 20, 4024–4034.[CrossRef]
    [Google Scholar]
  22. Sakurai, H., Williamson, R. A., Crowe, J. E., Beeler, J. A., Poignard, P., Bastidas, R. B., Chanock, R. M. & Burton, D. R. ( 1999; ). Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines. J Virol 73, 2956–2962.
    [Google Scholar]
  23. Sanders, M. T., Brown, L. E., Deliyannis, G. & Pearse, M. J. ( 2005; ). ISCOM-based vaccines: the second decade. Immunol Cell Biol 83, 119–128.[CrossRef]
    [Google Scholar]
  24. Schickli, J. H., Kaur, J., Ulbrandt, N., Spaete, R. R. & Tang, R. S. ( 2005; ). An S101P substitution in the putative cleavage motif of the human metapneumovirus fusion protein is a major determinant for trypsin-independent growth in vero cells and does not alter tissue tropism in hamsters. J Virol 79, 10678–10689.[CrossRef]
    [Google Scholar]
  25. Siber, G. R., Leombruno, D., Leszczynski, J., McIver, J., Bodkin, D., Gonin, R., Thompson, C. M., Walsh, E. E., Piedra, P. A. & other authors ( 1994; ). Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis 169, 1368–1373.[CrossRef]
    [Google Scholar]
  26. Skiadopoulos, M. H., Biacchesi, S., Buchholz, U. J., Riggs, J. M., Surman, S. R., Amaro-Carambot, E., McAuliffe, J. M., Elkins, W. R., St Claire, M. & other authors ( 2004; ). The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness. J Virol 78, 6927–6937.[CrossRef]
    [Google Scholar]
  27. Skiadopoulos, M. H., Biacchesi, S., Buchholz, U. J., Amaro-Carambot, E., Surman, S. R., Collins, P. L. & Murphy, B. R. ( 2006; ). Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity. Virology 345, 492–501.[CrossRef]
    [Google Scholar]
  28. Stills, H. F., Jr ( 2005; ). Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. ILAR J 46, 280–293.[CrossRef]
    [Google Scholar]
  29. Tang, R. S., Mahmood, K., Macphail, M., Guzzetta, J. M., Haller, A. A., Liu, H., Kaur, J., Lawlor, H. A., Stillman, E. A. & other authors ( 2005; ). A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys. Vaccine 23, 1657–1667.[CrossRef]
    [Google Scholar]
  30. Tristram, D. A., Welliver, R. C., Mohar, C. K., Hogerman, D. A., Hildreth, S. W. & Paradiso, P. ( 1993; ). Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18–36 months old. J Infect Dis 167, 191–195.[CrossRef]
    [Google Scholar]
  31. Tsui, P., Tornetta, M. A., Ames, R. S., Bankosky, B. C., Griego, S., Silverman, C., Porter, T., Moore, G. & Sweet, R. W. ( 1996; ). Isolation of a neutralizing human RSV antibody from a dominant, non-neutralizing immune repertoire by epitope-blocked panning. J Immunol 157, 772–780.
    [Google Scholar]
  32. Ulbrandt, N. D., Ji, H., Patel, N. K., Riggs, J. M., Brewah, Y. A., Ready, S., Donacki, N. E., Folliot, K., Barnes, A. S. & other authors ( 2006; ). Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J Virol 80, 7799–7806.[CrossRef]
    [Google Scholar]
  33. van den Hoogen, B. G., de Jong, J. C., Groen, J., Kuiken, T., de Groot, R., Fouchier, R. A. & Osterhaus, A. D. ( 2001; ). A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 7, 719–724.[CrossRef]
    [Google Scholar]
  34. van den Hoogen, B. G., Bestebroer, T. M., Osterhaus, A. D. & Fouchier, R. A. ( 2002; ). Analysis of the genomic sequence of a human metapneumovirus. Virology 295, 119–132.[CrossRef]
    [Google Scholar]
  35. van den Hoogen, B. G., van Doornum, G. J., Fockens, J. C., Cornelissen, J. J., Beyer, W. E., de Groot, R., Osterhaus, A. D. & Fouchier, R. A. ( 2003; ). Prevalence and clinical symptoms of human metapneumovirus infection in hospitalized patients. J Infect Dis 188, 1571–1577.[CrossRef]
    [Google Scholar]
  36. van den Hoogen, B. G., Herfst, S., Sprong, L., Cane, P. A., Forleo, E., de Swart, R. L., Osterhaus, A. D. & Fouchier, R. A. ( 2004; ). Antigenic and genetic variability of human metapneumoviruses. Emerg Infect Dis 10, 658–666.[CrossRef]
    [Google Scholar]
  37. Walsh, E. E., Hall, C. B., Briselli, M., Brandriss, M. W. & Schlesinger, J. J. ( 1987; ). Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection. J Infect Dis 155, 1198–1204.[CrossRef]
    [Google Scholar]
  38. Williams, J. V., Wang, C. K., Yang, C. F., Tollefson, S. J., House, F. S., Heck, J. M., Chu, M., Brown, J. B., Lintao, L. D. & other authors ( 2006; ). The role of human metapneumovirus in upper respiratory tract infections in children: a 20-year experience. J Infect Dis 193, 387–395.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.83084-0
Loading
/content/journal/jgv/10.1099/vir.0.83084-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error